Cargando…

Reproducibility and intratumoral heterogeneity of the PAM50 breast cancer assay

BACKGROUND: The PAM50 assay is used routinely in clinical practice to determine breast cancer prognosis and management; however, research assessing how technical variation and intratumoral heterogeneity contribute to misclassification and reproducibility of these tests is limited. METHODS: We evalua...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hurson, Amber N., Hamilton, Alina M., Olsson, Linnea T., Kirk, Erin L., Sherman, Mark E., Calhoun, Benjamin C., Geradts, Joseph, Troester, Melissa A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Epidemiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10147733/ https://www.ncbi.nlm.nih.gov/pubmed/36892725 http://dx.doi.org/10.1007/s10549-023-06888-1

Ejemplares similares

Research-based PAM50 signature and long-term breast cancer survival
por: Pu, Minya, et al.
Publicado: (2019)

Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification
por: Allott, Emma H., et al.
Publicado: (2016)

Predicting early breast cancer recurrence from histopathological images in the Carolina Breast Cancer Study
por: Shi, Yifeng, et al.
Publicado: (2023)

Bimodal age distribution at diagnosis in breast cancer persists across molecular and genomic classifications
por: Allott, Emma H., et al.
Publicado: (2019)

Development and verification of the PAM50-based Prosigna breast cancer gene signature assay
por: Wallden, Brett, et al.
Publicado: (2015)

TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays
por: Lin, Ching-Hung, et al.
Publicado: (2015)

Protein-based immune profiles of basal-like vs. luminal breast cancers
por: Walens, Andrea, et al.
Publicado: (2021)

PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer
por: Prat, A., et al.
Publicado: (2012)

Intratumor heterogeneity in HCC
por: Friemel, Juliane, et al.
Publicado: (2015)

Association of high obesity with PAM50 breast cancer intrinsic subtypes and gene expression
por: Kwan, Marilyn L, et al.
Publicado: (2015)

Characterization of uncertainty in the classification of multivariate assays: application to PAM50 centroid-based genomic predictors for breast cancer treatment plans
por: Ebbert, Mark TW, et al.
Publicado: (2011)

Analysis of the association of HER-2 low carcinomas and PAM50 assay in hormone receptor positive early-stage breast cancer
por: Terán, Santiago, et al.
Publicado: (2023)

A comparative study of PCS and PAM50 prostate cancer classification schemes
por: Yoon, Junhee, et al.
Publicado: (2021)

Evolutionary Dynamics of Intratumor Heterogeneity
por: Iwasa, Yoh, et al.
Publicado: (2011)

Targeting the intratumor heterogeneity in PMBL
por: Ritz, Olga, et al.
Publicado: (2014)

Intratumor and Intertumor Heterogeneity in Melanoma
por: Grzywa, Tomasz M., et al.
Publicado: (2017)

Intratumoral heterogeneity of intrahepatic cholangiocarcinoma
por: Walter, Dirk, et al.
Publicado: (2017)

Intratumoral Heterogeneity in Lung Cancer
por: Lv, Xiaodi, et al.
Publicado: (2023)

Toward Open and Reproducible Epidemiology
por: Mathur, Maya B, et al.
Publicado: (2023)

PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer
por: Martín, Miguel, et al.
Publicado: (2013)

Robust and interpretable PAM50 reclassification exhibits survival advantage for myoepithelial and immune phenotypes
por: Mathews, James C., et al.
Publicado: (2019)

Multi-Omic Regulation of the PAM50 Gene Signature in Breast Cancer Molecular Subtypes
por: Ochoa, Soledad, et al.
Publicado: (2020)

Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer
por: Veerla, Srinivas, et al.
Publicado: (2023)

Risk of cervical abnormality after age 50 in women with previously negative smears
por: Blanks, R G, et al.
Publicado: (2009)

Unifying models of glioblastoma’s intratumoral heterogeneity
por: Lam, K H Brian, et al.
Publicado: (2020)

Measuring Intratumoral Heterogeneity of Immune Repertoires
por: Yuzhakova, Diana Vladimirovna, et al.
Publicado: (2020)

Intratumor Heterogeneity in Early Lung Adenocarcinoma
por: Senosain, Maria-Fernanda, et al.
Publicado: (2020)

Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter Study
por: Kjällquist, Una, et al.
Publicado: (2022)

Intratumor DNA methylation heterogeneity in glioblastoma: implications for DNA methylation-based classification
por: Wenger, Anna, et al.
Publicado: (2019)

Mammographic screening before age 50 years in the UK: comparison of the radiation risks with the mortality benefits
por: Berrington de González, A, et al.
Publicado: (2005)

Lifestyle and reproductive risk factors associated with anal cancer in women aged over 50 years
por: Coffey, K, et al.
Publicado: (2015)

Genetic Background May Contribute to PAM50 Gene Expression Breast Cancer Subtype Assignments
por: Hu, Ying, et al.
Publicado: (2013)

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
por: Schettini, Francesco, et al.
Publicado: (2021)

Sample Preparation Approach Influences PAM50 Risk of Recurrence Score in Early Breast Cancer
por: Lien, Tonje G., et al.
Publicado: (2021)

Discordance between PAM50 intrinsic subtyping and immunohistochemistry in South African women with breast cancer
por: Dix-Peek, Thérèse, et al.
Publicado: (2023)

A 50% higher prevalence of life-shortening chronic conditions among cancer patients with low socioeconomic status
por: Louwman, W J, et al.
Publicado: (2010)

Factors associated with the age of the onset of diabetes in women aged 50 years or more: a population-based study
por: Valadares, Ana L R, et al.
Publicado: (2014)

The significance of intertumor and intratumor heterogeneity in liver cancer
por: Liu, Jinping, et al.
Publicado: (2018)

Clinical significance of intratumor heterogeneity for gynecological carcinoma
por: Yang, Ying-Chao, et al.
Publicado: (2015)

Intratumoral heterogeneity of the therapeutical response to gemcitabine and metformin
por: Zechner, Dietmar, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_jgvnr6l6urhr9kj8omun3ua54r